Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...
PARIS, June 11, 2026 (GLOBE NEWSWIRE) -- Proof of Pitch returned to the Louvre Palace on June 2 and 3 for its fourth edition, and two startups left Paris as winners. ReplyCorp took the General Track, and Parthenon won the Canton Track after live pitches in front of one of the strongest investor juries in Web3.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that it has filed a short form base shelf prospectus (the “Shelf Prospectus”) dated June 10, 2026 with the securities regulatory authorities in all provinces and territories of Canada. The Shelf Prospectus replaces the Company’s prior short form base shelf prospectus, which was set to expire on June 17, 2026.
HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- AIC Inc., a leading provider of enterprise storage and server solutions, will showcase its latest AI storage...
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Martinrea International Inc. (“Martinrea” or the “Company”) (TSX : MRE), a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, today announced the results of the election of directors at its annual general meeting.
TORONTO, June 10, 2026 /PRNewswire/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...
TORONTO, June 10, 2026 /CNW/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...